Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015-2020. 2021

Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato

Despite the importance of pharmacies in ensuring medications and health care needs are met, there is limited up-to-date information regarding access to pharmacies or their services in the United States. To evaluate trends and disparities in access to pharmacies in 4 largest cities in the United States, New York City, Los Angeles, Houston, and Chicago, by neighborhood racial and ethnic composition from 2015 to 2020. Data from the National Council for Prescription Drug Programs (2015-2020) and the American Community Survey (2015-2019) were used. We examined neighborhoods (i.e., census tracts) and evaluated disparities in "pharmacy deserts" (low-income neighborhoods (1) whose average distance to the nearest pharmacy was at least 1 mile or (2) whose average distance to the nearest pharmacy was at least 0.5 mile and at least 100 households had no vehicle access). We also evaluated the differences in pharmacy closures and the availability of pharmacy services. From 2015 to 2020, the percent of neighborhoods with pharmacy deserts declined in New York City (from 1.6% to 0.9% of neighborhoods, P < 0.01), remained stable in Los Angeles (13.7% to 13.4%, P = 0.58) and Houston (27.0% to 28.5%, P = 0.18), and increased in Chicago (15.0% to 19.9%, P < 0.01). Pharmacy deserts were persistently more common in Black and Latino neighborhoods in all 4 cities. As of 2020, pharmacies in Black and Latino neighborhoods were also more likely to close and less likely to offer immunization, 24-hour, and drive-through services than pharmacies in other neighborhoods. To reduce disparities in access to medications and health care services, including those in response to the coronavirus disease 2019 pandemic (e.g., testing and vaccinations), policies that improve pharmacy access and expand the provision of pharmacy services in minority neighborhoods are critical.

UI MeSH Term Description Entries
D009519 New York City City located at the mouth of the Hudson River, in New York State.
D010593 Pharmaceutical Services Total pharmaceutical services provided by qualified PHARMACISTS. In addition to the preparation and distribution of medical products, they may include consultative services provided to agencies and institutions which do not have a qualified pharmacist. Pharmaceutic Services,Pharmaceutical Care,Pharmacy Services,Services, Pharmaceutic,Services, Pharmaceutical,Services, Pharmacy,Care, Pharmaceutical,Pharmaceutic Service,Pharmaceutical Service,Pharmacy Service,Service, Pharmaceutic,Service, Pharmaceutical,Service, Pharmacy
D010594 Pharmacies Facilities for the preparation and dispensing of drugs. Community Pharmacies,Pharmacy Distribution,Community Pharmacy,Distribution, Pharmacy,Distributions, Pharmacy,Pharmacies, Community,Pharmacy Distributions,Pharmacy, Community
D002641 Chicago A city in Illinois.
D006297 Health Services Accessibility The degree to which individuals are inhibited or facilitated in their ability to gain entry to and to receive care and services from the health care system. Factors influencing this ability include geographic, architectural, transportational, and financial considerations, among others. Access To Care, Health,Access to Care,Access to Contraception,Access to Health Care,Access to Health Services,Access to Medications,Access to Medicines,Access to Therapy,Access to Treatment,Accessibility of Health Services,Availability of Health Services,Contraception Access,Contraceptive Access,Medication Access,Accessibility, Health Services,Contraceptive Availability,Health Services Geographic Accessibility,Program Accessibility,Access to Cares,Access to Contraceptions,Access to Medication,Access to Medicine,Access to Therapies,Access to Treatments,Access, Contraception,Access, Contraceptive,Access, Medication,Accessibilities, Health Services,Accessibility, Program,Availability, Contraceptive,Care, Access to,Cares, Access to,Contraception, Access to,Contraceptive Accesses,Health Services Availability,Medication Accesses,Medication, Access to,Medicine, Access to,Medicines, Access to,Therapy, Access to,Treatment, Access to
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015141 Los Angeles City in California.

Related Publications

Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
May 2004, The Journal of infectious diseases,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
February 2020, Environment & planning A,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
January 2021, Journal of the American Pharmacists Association : JAPhA,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
January 2021, The American journal of emergency medicine,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
November 2007, Journal of urban health : bulletin of the New York Academy of Medicine,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
December 1973, Science (New York, N.Y.),
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
February 1997, JAMA,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
October 2006, Environmental health perspectives,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
April 2018, Injury epidemiology,
Jenny S Guadamuz, and G Caleb Alexander, and Shannon N Zenk, and Genevieve P Kanter, and Jocelyn R Wilder, and Dima M Qato
October 2005, American journal of public health,
Copied contents to your clipboard!